MeMed raises $93M to accelerate commercialization of its hos

MeMed raises $93M to accelerate commercialization of its host immune-response product portfolio MeMed BV test recently cleared for use by US FDA to aid in distinguishing between bacterial and

Related Keywords

Boston , Massachusetts , United States , Phoenix , Arizona , Israel , Kostenloser Wertpapierhandel , Patrick Zhang , Kfir Emmer , Us Department Of Defense , Caesara Medical Holdings , Technology Investment , Eu Commission , Drug Administration , Union Tech Ventures , Consilium Strategic Communications , Memed Key , Horizons Ventures , Shavit Capital , Social Capital , Touchwood Capital , Clai Insurance , Phoenix Insurance , Poalim Equity , Western Technology , Med Contacts , Will Harris , Memed , Raises , Ccelerate , Ommercialization , Most , Immune , Response , Product , Portfolio ,